98% Injectable Polypeptide Hormones Terlipressin Acetate

98% Injectable Polypeptide Hormones Terlipressin Acetate CAS 14636-12-5 Terlipressin For Norepinephrine-resistant Septic Shock & Aggregation
Quick Details :

Terlipressin Acetate
Cas No.: 14636-12-5

Email :bodybuilding03@yuanchengtech.com

Skype:husiyuyc@outlook.com
Web:http://www.yccreate.com

EINECS: 238-680-8
Molecular Formula: C52H74N16O15S2
M.S.:
Terlipressin Acetate CAS 14636-12-5 Polypeptide Hormones Powder For Norepinephrine-resistant
Molecular Weight: 1227.37
Purity (HPLC): 98.0%min.
Appearance: White powder
Single Impurity (HPLC): 1.0%max
Amino Acid Composition: ±10% of theoretical
Peptide Content (N%): >=80.0%
Water Content(Karl Fischer):>=10.0%
Specific Rotation (20/D): -95.0~-105.0°(c=1 1%HAc)
Acetate Content (HPIC): <=15.0%
MS(ESI): Consistent
Mass Balance: 95.0~105.0%
Grade : Pharmaceutical Grade
Storage: Closed, below 2 ~ 8℃ preservation
Usage : Norepinephrine-resistant septic shock, bleeding esophageal varices, and for the complications of cirrhosis of the liver (esophageal and gastric variceal bleeding, ascites, liver and kidney syndrome) has important significance for the treatment of patients

Description:

Terlipressin (trade names Teripress by New Medicon Pharma and Glypressin by Ferring Pharmaceuticals) is an analogue of vasopressin used as a vasoactive drug in the management of hypotension. It has been found to be effective when norepinephrine does not help.
Indications for use include norepinephrine-resistant septic shock and hepatorenal syndrome. In addition, it is used to treat bleeding esophageal varices.
Between the patients with cirrhosis of the liver into the portal circulation of each vein and venous congestion can occur in vascular anastomosis, portal vein pressure rise phenomenon. The most frequently appeared in the azygos vein anastomosis with lower esophageal varices, instant tube.

Application:

This product is pressurized prodrug hormone, vasopressin glycyl in injection into the blood after enzymatic hydrolysis in the molecule is produced a continuous low level. The portal venous pressure it generates the desired effect, but the changes of arterial blood pressure than the use of vasopressin after much smaller, and the blood of a few do not increase the fibrinolytic. Push once its role can be maintained for about 4 ~ 6h.
Intravenous injection, 2mg, every 4 ~ 6h again, until the control, use at most 24h. It is not for children.